Protocol
12-232
Full Title
A Single Arm Clinical Trial Investigating the Feasibility of a Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms
Purpose
Many women who undergo cancer treatment report experiencing vaginal dryness or discomfort, a common symptom of a decrease in or lack of estrogen. Women who had hormone receptor-positive breast or endometrial cancer may be unable to take hormonal supplements to treat these symptoms.
The purpose of this study is to evaluate the effectiveness of a non-hormonal vaginal gel called hyaluronic acid (HyaloGYN) in women reporting vaginal dryness or discomfort after treatment for breast or endometrial cancer. HyaloGYN is commercially available and has been shown to be effective for relieving vaginal symptoms in women without cancer.
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Participants in this study must be postmenopausal women who completed primary treatment for hormone receptor-positive breast cancer or endometrial cancer at least 3 months but no more than 5 years before entering the study.
- Women with breast cancer must be taking an aromatase inhibitor.
- Women who had endometrial cancer must have had a hysterectomy and radiation therapy.
- Participants must report vaginal dryness or discomfort.
- This study is open to women age 18 and older.
For more information about this study, please contact Dr. Jeanne Carter at 646-888-5076.
Disease(s)
Breast Cancer
Endometrial and other Uterine Cancers: Endometrial Cancer
Survivorship
Locations
ClinicalTrials.gov
Related Diseases
